Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

31, 2008. The six month increase is primarily the result of net sales, offset by our repurchase of $45 million principal amount of our senior convertible notes. Cash flow provided by operating activities for the six months ended June 30, 2009 was $15.9 million.

Looking ahead in 2009

ViroPharma is revising its guidance for the year 2009. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $80 to $95 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $135 to $145 million, which includes approximately $18 million of maribavir-related expenses. SFAS 123R expenses are expected to be between $11 and $13 million.

The company is providing Cinryze net sales guidance and withdrawing Vancocin net sales guidance to align the company's guidance with its growth driver and in light of the August 4, 2009 FDA advisory committee regarding proposed bioequivalence recommendations for Vancocin.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on July 29, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 "After ... people who don’t stand very often, I decided that there ... longer periods during the day," said a concerned inventor from ... can’t stand for long periods. It builds endurance and keeps ... promote better health. Easy to use and producible in design ...
(Date:8/29/2014)... New Delhi, India (PRWEB) August 29, 2014 ... marketing firm, has recently launched a new service named ... is a research based service. Before tailoring the service, ... being provided by other companies. The company has done ... must be impeccable and able to deliver outstanding results ...
(Date:8/29/2014)... basic life support (BLS) videos available on YouTube ... guidelines, according to a new study published in ... the Australasian College for Emergency Medicine (ACEM). ... arrest are known to improve survival for,victims. , ... together the study, which reviewed educational videos from ...
(Date:8/29/2014)... has caused disease outbreaks across the Arabian Peninsula and ... has claimed the lives of several hundred people since ... have been puzzled over how easily the pathogen spreads ... led by virologists from the University of Bonn have ... the rate of human transmission is low. Still, a ...
(Date:8/29/2014)... 2014 The Fresh Diet, America’s premier ... new Fresh Vegetarian meal plan. Originating from The Fresh ... new menu is designed to satisfy customers seeking a ... , Responding to the growing demand by customers ... dollar market (Forbes) with 14% of Americans identifying vegetarian ...
Breaking Medicine News(10 mins):Health News:Ethane Web Technologies Launches a New Web Design Service 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3
... area health care organizations agree that today,s tough ... organizations provided tips for Ohioans to stay healthy. , ... Columbus, Central Ohio Diabetes Association, Columbus Dietetic Association, Lilly ... Ohio Association of Free Clinics, Ohio Department of Health ...
... found parents still show a gender bias, however , MONDAY, ... join a sports team or be active if their parents ... 681 parents and 433 fourth- and fifth-grade students at 12 ... both boys and girls -- of parents who valued high-intensity ...
... and Company (NYSE: LLY ) announced today ... and Drug Administration (FDA) for ALIMTA(R) (pemetrexed for injection). ... maintenance therapy for locally advanced or metastatic non-small cell ... histology whose disease has not progressed after four cycles ...
... 6 DynaVox Systems LLC, the world,s ... with speech, language and learning disabilities, today announced that ... acquisition reinforces DynaVox,s commitment to providing the appropriate communication ... the company,s position as the market leader in the ...
... RATON, Fla., July 6 After 25 years in the ... other fitness classes, Dale Buchanan, a Washington, DC native, has ... it to South Florida in his new studio located in ... combination of High Intensity Fitness Training and T,ai Chi. , ...
... Coapt Systems, Inc. ( www.coaptsystems.com ) ... acid based dermal filler for the treatment of facial ... Hydrelle is the first FDA-approved hyaluronic acid filler ... Proven safe and effective, Hydrelle is also a ...
Cached Medicine News:Health News:Top 10 Tips for Staying Healthy When Money is Tight 2Health News:Top 10 Tips for Staying Healthy When Money is Tight 3Health News:Kids of Parents Who Value Exercise Are More Active 2Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 2Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 3Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 4Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 5Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 6Health News:Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) 7Health News:DynaVox Systems LLC Merges with Blink Twice 2Health News:DynaVox Systems LLC Merges with Blink Twice 3Health News:Boca Raton, FL Becomes Home of Dale Buchanan's Supreme Ultimate Fitness 2Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 2Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 3Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 4
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... market research report is available in its ... Market Forecast 2014-2024 ... Needle-free delivery – discover technological and commercial ... the needle-free delivery market? Visiongain,s brand new ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2
... , , , , , , SEATTLE, Dec. 28 Cell ... December 24, 2009, CTI,s Board of Directors (the "Board of Directors") ... which one preferred stock purchase right will be distributed for each ... 7, 2010. Initially, the rights are not exercisable, and are attached ...
... , , REDWOOD CITY, Calif., Dec. 24 ... focused on the development of improved versions of protein drugs, ... tender offer, which expired at 5:00 p.m., New York City ... the preliminary count by the depositary for the tender offer, ...
Cached Medicine Technology:Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 2Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 3Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 4Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2
... self-contained work area that will help protect ... bulbs irradiate the work area prior to ... will be amplified. Containment features reduce the ... has acrylic windows for a clear view, ...
Remote Alpha Dock system for the DNA Engine line, allows, Alpha unit to function remotely (requires fan power supply)...
... designed for highthroughput reading of tube racks. Its ... less than one second per rack, making it ... design of the reader allows a rack to ... by robotic arms. An optical safety switch prevents ...
... stainless steel work surface. ... vibration to protect operator, ... vibration-producing equipment from the ... allows for multiple vibration-free ...
Medicine Products: